US Clinical Laboratories Acquires Georgia's Augusta Lab

By Kirell Lakhman

Clinical labs in Augusta, Ga., just got some renewed competition.

Texas-based US Clinical Laboratories has acquired Georgia's Augusta Laboratory for an undisclosed sum, marking USCL's second lab buy in the state in five weeks.

Founded in 1985, Augusta Lab serves northeastern Georgia and specializes in servicing nursing and skilled-nursing homes, and provides walk-in testing in Augusta, where it is based.

Terms of the deal will enable Augusta Lab founder and President Jan Schöler to retain his existing position, and will require him to oversee the labs' integration and USCL's ongoing strategy of expanding into neighboring states.

Indeed, the buy "is a good illustration of our strategy of entering markets where we can obtain the synergies of multiple acquisitions as well as the prospect of strong internal growth," USCL CEO Rod Proto said.

As I wrote in June, the Augusta Lab deal follows USCL's acquisition of Vidalia Lab Services for an undisclosed sum. That deal marked the lab's first foray beyond its home base of Houston.

Both buys enable USCL to "offer our testing services to the eastern half of Georgia on a very cost effective basis," Proto said, adding that "the combination of our existing capabilities with those of Augusta Lab will offer the opportunity to bring services to clients that Augusta Lab has not traditionally served."

Founded in 2010, privately held USCL was indeed "created … to pursue opportunities and growth strategies in the laboratory-testing industry."

With the Augusta Lab acquisition, the company now has five lab and 14 draw stations.

News of the deal comes on the same day as another lab, Solstas Lab Partners, announced its acquisition of a trio of labs — one based in Birmingham, Ala. and two located in Wilmington, Del. — as part of its own strategy to significantly expand east and west of its Greensboro, NC, headquarters.


Got a tip? Click my byline above to send it along or submit it as a comment below. Follow my headlines on Twitter or subscribe to my RSS feed. Learn more about me or become a source via Linkedin, where all conversations are confidential.